Literature DB >> 29111320

Clinical states of cirrhosis and competing risks.

Gennaro D'Amico1, Alberto Morabito2, Mario D'Amico3, Linda Pasta4, Giuseppe Malizia4, Paola Rebora5, Maria Grazia Valsecchi5.   

Abstract

The clinical course of cirrhosis is mostly determined by the progressive increase of portal hypertension, hyperdynamic circulation, bacterial translocation and activation of systemic inflammation. Different disease states, encompassing compensated and decompensated cirrhosis and a late decompensated state, are related to the progression of these mechanisms and may be recognised by haemodynamic or clinical characteristics. While these disease states do not follow a predictable sequence, they correspond to varying mortality risk. Acute-on-chronic liver failure may occur either in decompensated or in compensated cirrhosis and is always associated with a high short-term mortality. The increasing severity of these disease states prompted the concept of clinical states of cirrhosis. A multistate approach has been considered to describe the clinical course of the disease. Such an approach requires the assessment of the probabilities of different outcomes in each state, which compete with each other to occur first and mark the transition towards a different state. This requires the use of competing risks analysis, since the traditional Kaplan-Meier analysis should only be used in two-state settings. Accounting for competing risks also has implications for prognosis and treatment efficacy research. The aim of this review is to summarise relevant clinical states and to show examples of competing risks analysis in multistate models of cirrhosis.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Clinical course of cirrhosis; Clinical states of cirrhosis; Competing risks; Cumulative incidence function; Multistate models for cirrhosis; Portal hypertension

Mesh:

Year:  2017        PMID: 29111320     DOI: 10.1016/j.jhep.2017.10.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  65 in total

1.  Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.

Authors:  Banishree Saha; David Tornai; Karen Kodys; Adeyinka Adejumo; Patrick Lowe; Craig McClain; Mack Mitchell; Arthur McCullough; Srinivasan Dasarathy; Aimee Kroll-Desrosiers; Bruce Barton; Svetlana Radaeva; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-05-27       Impact factor: 17.425

2.  Post-operative Ascites After Hepatectomy-Not More Than What Meets the Eyes.

Authors:  Sri Siddhartha Nekkanti; Sridhar Sundaram; Shraddha Patkar; Mahesh Goel
Journal:  J Gastrointest Surg       Date:  2021-06-15       Impact factor: 3.452

3.  Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment.

Authors:  Francesco Verde; Valeria Romeo; Simone Maurea
Journal:  Quant Imaging Med Surg       Date:  2020-03

4.  A Simplified Algorithm for the Management of Hepatitis C Infection.

Authors:  Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-05

Review 5.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

6.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

7.  Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.

Authors:  Anshuman Elhence; Abhinav Anand; Sagnik Biswas; Manas Vaishnav; Rajni Yadav; Prasenjit Das; Rajesh Panwar; Sandeep Agarwal; Shivanand Gamanagatti; Ramesh Kumar
Journal:  Dig Dis Sci       Date:  2022-06-07       Impact factor: 3.199

8.  The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.

Authors:  Rémy Schwarzer; Thomas Reiberger; Mattias Mandorfer; Danijel Kivaranovic; Silvia Hametner; Stephanie Hametner; Rafael Paternostro; Bernhard Scheiner; Jenifer Schneeweiss-Friedl; Michael Trauner; Rainer Schoefl; Andreas Maieron
Journal:  J Gastroenterol       Date:  2019-12-12       Impact factor: 7.527

9.  Cirrhosis regression after SVR with indirect methods of fibrosis analysis: How far is it real?

Authors:  Walnei Fernandes Barbosa; Vanessa Gutierrez Andrade; Aline Márcia Marques Braz; Fernanda Cristina Winckler; Livia Roma Barbosa; Márjorie de Assis Golim; Liciana Vaz de Arruda Silveira; Rafael Plana Simões; Giovanni Faria Silva
Journal:  Clin Exp Med       Date:  2021-08-04       Impact factor: 3.984

10.  Diagnosing Portal Hypertension with Noninvasive Subharmonic Pressure Estimates from a US Contrast Agent.

Authors:  Ipshita Gupta; John R Eisenbrey; Priscilla Machado; Maria Stanczak; Corinne E Wessner; Colette M Shaw; Sriharsha Gummadi; Jonathan M Fenkel; Alison Tan; Cynthia Miller; Julia Parent; Susan Schultz; Michael C Soulen; Chandra M Sehgal; Kirk Wallace; Flemming Forsberg
Journal:  Radiology       Date:  2020-11-17       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.